{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:46:51Z","timestamp":1792000011870,"version":"4.4.0"},"reference-count":19,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Thyroid\u00ae"],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The optimal duration of antithyroid drug (ATD) therapy in Graves\u2019 disease is uncertain. Although guidelines recommend 12\u201318 months, shorter courses may be sufficient in selected patients. We evaluated whether ATD duration &lt;12 months is non-inferior to 12\u201318 months for relapse among patients with Graves\u2019 disease and lower thyrotropin receptor antibody (TRAb) levels (&gt;1.8 and &lt;10.0 U\/L) at diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      We analyzed real-world data from adults with Graves\u2019 disease and baseline TRAb &lt;10 U\/L treated with ATDs at a single center. The primary endpoint was relapse within 12 months of ATD cessation. A prespecified risk-difference non-inferiority framework was used, with a primary margin of +5% and an exploratory margin of +10%. Treatment effects were estimated using unadjusted analyses, inverse-probability-of-treatment weighting (IPTW;\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 369), and 1:1 propensity-score matching (PSM; 104 matched pairs). Secondary outcomes included long-term relapse (median follow-up 58 months), TRAb levels at cessation, and restricted mean survival time (RMST) over 60 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings:<\/jats:title>\n                    <jats:p>At 12 months, relapse occurred in 23\/134 (17.2%) patients treated &lt;12 months and 48\/235 (20.4%) treated for 12\u201318 months. The IPTW-adjusted risk difference was \u20131.5% (CI \u201311.0 to +8.0), meeting the 10% but not the 5% non-inferiority margin. The unadjusted estimate (\u20133.2%) met both margins, whereas the PSM estimate (+2.9%, CI \u20137.3 to +13.1) met neither because of reduced precision. Long-term outcomes were similar between groups (IPTW Cox HR 0.92 [CI 0.65\u20131.31]; RMST difference +3.2 months over 60 months [\u20132.1 to +8.4]). TRAb levels at cessation were comparable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Among patients with Graves\u2019 disease and lower TRAb levels, shorter ATD courses (&lt;12 months) produced outcomes broadly comparable to 12\u201318 months. Although strict non-inferiority was not confirmed at a 5% margin, findings meeting an exploratory 10% threshold support TRAb-guided individualization of ATD duration and justify prospective randomized evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10507256261470303","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:08:23Z","timestamp":1784628503000},"page":"961-969","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Shorter Versus Standard Antithyroid Drug Therapy in Graves\u2019 Disease with Lower Baseline Thyrotropin Receptor Antibody (TRAb) Levels: Relapse Outcomes from a Propensity-Weighted Analysis"],"prefix":"10.1177","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9047-1556","authenticated-orcid":false,"given":"Salman","family":"Razvi","sequence":"first","affiliation":[{"name":"Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK."},{"name":"Department of Endocrinology, Queen Elizabeth Hospital, Gateshead, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"Holley","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences and Wellbeing, School of Medicine, University of Sunderland, Sunderland, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Wheeler","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Queen Elizabeth Hospital, Gateshead, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Vernazza","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Queen Elizabeth Hospital, Gateshead, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Stewart","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Queen Elizabeth Hospital, Gateshead, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon H.S.","family":"Pearce","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK."},{"name":"Endocrine Unit, Royal Victoria Infirmary, Newcastle upon Tyne, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kilimangalam","family":"Narayanan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Queen Elizabeth Hospital, Gateshead, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Tsatlidis","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Queen Elizabeth Hospital, Gateshead, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02016-0"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00005-0"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae222"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-021-01730-1"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1159\/000490384"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0229"},{"key":"e_1_3_3_8_1","unstructured":"7.National Institute for Health and Care Excellence. Thyroid disease: Assessment and management (NG145). NICE: London; 2019 (updated 2023). Available from: https:\/\/www.nice.org.uk\/guidance\/ng145 [Last accessed: March3 2026]."},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/cen.70003"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-3644"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2004.02135.x"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.K06-069"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-22-0226"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5945178"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2025.2405"},{"key":"e_1_3_3_16_1","volume-title":"Assessment of iodine deficiency disorders and monitoring their elimination: a guide for programme managers","author":"World Health Organization","year":"2007","unstructured":"15.World Health Organization. Assessment of iodine deficiency disorders and monitoring their elimination: a guide for programme managers. World Health Organization: Geneva; 2007. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/43781"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2007.0315"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/jech.2004.029496"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3697"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01937-w"}],"container-title":["Thyroid\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10507256261470303","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10507256261470303","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10507256261470303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:02:55Z","timestamp":1791997375000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10507256261470303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"alternative-id":["10.1177\/10507256261470303"],"URL":"https:\/\/doi.org\/10.1177\/10507256261470303","relation":{},"ISSN":["1050-7256","1557-9077"],"issn-type":[{"value":"1050-7256","type":"print"},{"value":"1557-9077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]}}}